Overview

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Shanghai Huaota Biopharmaceutical Co., Ltd.